大藤 正雄¹, 松谷 正一¹, 水本 英明¹, 木村 健², 上野 規男², 冨山 剛², 小池 正³, 川内 章裕³, 伊藤 洋二³, 大熊 稔⁴, 北村 次男⁵, 田中 幸子⁵, 藤堂 彰男⁶, 冨田 周介⁶, 工藤 正俊⁶, 小川 暢也⁷, 尾前 照雄⁸, 山村 秀夫⁹

Masao OHTO¹, Shoichi MATSUTANI ¹, Hideaki MIZUMOTO¹, Ken KIMURA², Norio UENO², Takeshi TOMIYAMA², Tadashi KOIKE³, Akihiro KAWAUCHI ³, Yoji ITO³, Minoru OHKUMA⁴, Tsugio KITAMRA⁵, Sachiko TANAKA⁵, Akio TODO⁶, Shusuke TOMITA⁶, Masatoshi KUDO⁶, Nobuya OGAWA⁷, Teruo OMAE⁸, Hideo YAMAMURA⁹

¹千葉大学第1内科, ²自治医科大学消化器内科, ³昭和大学外科, ⁴京都大学第1内科, ⁵大阪府立成人病センター消化器内科, ⁶神戸市立中央市民病院消化器内科, ⁷愛媛大学薬理学, ⁸国立循環器病センター, ⁹康済会病院

¹First Department of Medicine Chiba University School of Medicine, ² , ³ , ⁴ , ⁵ , ⁶ , ⁷ , ⁸ , ⁹

キーワード : Color Doppler flow imaging, Contrast echography, Liver tumor

In this phase II clinical study, three different doses of a saccharide-based ultrasound contrast agent, SH/TA-508, were injected intravenously into 88 patients with liver tumors that required color Doppler flow imaging. Changes in color Doppler images of tumors, and the safety and usefulness of SH/TA-508 were evaluated. Appropriate signal enhancement in color Doppler images was obtained in more than 70% of the patients. Optimal images were obtained more frequently at doses with a concentration of 300 or 400 mg/ml, rather than 200 mg/ml. Transient pain, cool sensation at the site of injection, and other adverse events were observed in 6 (7%) patients. These results suggest that an initial dose of 5 ml at a concentraion of 300 mg/ml is sufficient to obtain satisfactory color Doppler images in liver tumor.